Search

Your search keyword '"Generalized anxiety disorder -- Drug therapy"' showing total 10 results
Start Over Descriptor "Generalized anxiety disorder -- Drug therapy" Publication Year Range Last 3 years
10 results on '"Generalized anxiety disorder -- Drug therapy"'

1. LSD Drug Candidate Gets Breakthrough Tx Status for Generalized Anxiety Disorder

Author

Park, Brian

Subjects
United States. Food and Drug Administration, Drug therapy, Generalized anxiety disorder -- Drug therapy, Tranquilizing agents, LSD (Drug), Tranquilizing drugs
Abstract

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to MM120 (lysergide d-tartrate) for the treatment of generalized anxiety disorder (GAD). MM120 is a tartrate salt form of [...]

Published
2024

2. Data on Generalized Anxiety Disorders Described by Researchers at Central Michigan University (Fecal Microbiota Transplant On escherichia-shigella Gut Composition and Its Potential Role In the Treatment of Generalized Anxiety Disorder

Subjects
Drug therapy, Generalized anxiety disorder -- Drug therapy, Microbiota (Symbiotic organisms), Mental health
Abstract

2024 JUN 10 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- A new study on Mental Health Diseases and Conditions - Generalized Anxiety Disorders [...]

Published
2024

3. FDA Grants Breakthrough Therapy Designation to LSD-Based Treatment for Generalized Anxiety Disorder: Mind Medicine's lysergide d-tartrate (MM-120) demonstrated statistically significant and clinically meaningful improvements in anxiety symptoms in findings from a phase 2b study

Author

Meara, Killian

Subjects
Drug therapy, Generalized anxiety disorder -- Drug therapy, LSD (Drug)
Abstract

Mind Medicine has received breakthrough therapy designation from the FDA for its lysergide d-tartrate (MM-120) therapy to treat patients with generalized anxiety disorder (GAD), the biopharmaceutical company announced in a [...]

Published
2024

4. Lexapro Approved for Generalized Anxiety Disorder in Children

Author

Ernst, Diana

Subjects
United States. Food and Drug Administration, Lexapro (Medication), Drug therapy, Generalized anxiety disorder -- Drug therapy, Child health, Pediatrics, Drug approval, Escitalopram, Children -- Health aspects
Abstract

The Food and Drug Administration (FDA) has approved Lexapro (escitalopram) for the treatment of generalized anxiety disorder (GAD) in pediatric patients 7 years of age and older. Previously, the treatment [...]

Published
2023

5. MindMed Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal

Subjects
Testing, Drug therapy, Product development, Generalized anxiety disorder -- Drug therapy, LSD (Drug) -- Testing, Biotechnology industries -- Product development, Biotechnology industry -- Product development
Abstract

2022 SEP 24 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the 'Company' or 'MindMed'), [...]

Published
2022

6. Research on Anxiety Disorders Detailed by a Researcher at Pondicherry Institute of Medical Sciences (Prevalence of generalized anxiety disorder among patients attending medicine outpatient department in a tertiary care center: A cross-sectional ...)

Subjects
Drug therapy, Generalized anxiety disorder -- Drug therapy, Mental health
Abstract

2024 FEB 12 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- New study results on anxiety disorders have been published. According to news reporting [...]

Published
2024

7. Sunovion & Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder

Subjects
Sunovion Pharmaceuticals Inc., Generalized anxiety disorder -- Drug therapy, Pharmaceutical industry, General interest, News, opinion and commentary
Abstract

MARLBOROUGH: Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in a Phase 2/3 clinical study evaluating ulotaront, [...]

Published
2023

8. Sunovion and Otsuka Initiate Clinical Development of Ulotaront for the Treatment of Generalized Anxiety Disorder

Subjects
Sunovion Pharmaceuticals Inc., Otsuka Holdings Company Ltd., Otsuka Pharmaceutical Company Ltd., Generalized anxiety disorder -- Drug therapy, Health products industry, Pharmaceutical industry, Business, Business, international
Abstract

-Approximately 7.5 Million People in The U.S. Are Living with Generalized Anxiety Disorder (GAD) 1,2- MARLBOROUGH, Mass. & PRINCETON, N.J. -- Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & [...]

Published
2023

10. New Findings from Yunnan in the Area of Generalized Anxiety Disorders Published (Analysis of the Underlying Mechanism of the Jiu Wei Zhen Xin Formula for Treating Generalized Anxiety Disorder Based on Network Pharmacology of Traditional Chinese ...)

Subjects
Drug therapy, International economic relations, Reports, Generalized anxiety disorder -- Drug therapy, Evidence-based medicine -- Reports
Abstract

2022 JUN 13 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- New study results on generalized anxiety disorders have been published. According to news [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results